What is Synchron?
Synchron is at the forefront of neurotechnology, pioneering the development of minimally invasive brain-computer interfaces (BCIs). Their flagship technology, the Stentrode system, is designed to empower individuals with paralysis by enabling hands-free digital control. Beyond assistive applications, Synchron's innovations are poised to revolutionize next-generation neural decoding, opening avenues for everyday digital interaction and advanced neurological research. The company's focus on creating accessible and effective BCIs positions it as a key player in the rapidly evolving medtech and neurotech sectors.
How much funding has Synchron raised?
Synchron has raised a total of $275M across 2 funding rounds:
Series C
$75M
Series D
$200M
Series C (2022): $75M with participation from Bezos Expeditions and ARCH VENTURE PARTNERS
Series D (2025): $200M led by Bezos Expeditions, ARCH VENTURE PARTNERS, Double Point Ventures, and Khosla Ventures
Key Investors in Synchron
Bezos Expeditions
Bezos Expeditions is an investment firm founded by Jeff Bezos that focuses on a diverse range of sectors including technology, healthcare, and space exploration. The firm is known for its strategic investments in innovative companies such as Airbnb, Uber, and Twitter. Its intended clients include startups and established businesses seeking funding and support for growth.
ARCH VENTURE PARTNERS
ARCH Venture Partners is a leading earlystage venture capital firm that creates and invests in life sciences and advanced technology companies, often cofounding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Double Point Ventures
Double Point Ventures is a venture capital firm focused on investing in innovative healthcare companies that are shaping the future of medicine. They specialize in therapeutics, diagnostics, digital health, and healthcare services, providing not just capital but also strategic partnerships and industry expertise to accelerate growth.
What's next for Synchron?
The recent major strategic investment signifies Synchron's readiness for accelerated scaling and market penetration. With substantial backing, the company is expected to advance its Stentrode system through further clinical trials, regulatory approvals, and manufacturing scale-up. This infusion of capital will likely fuel research and development into new applications for neural decoding, potentially expanding into areas beyond paralysis treatment. Synchron's strategic partnerships and continued investor support suggest a clear path toward commercialization and establishing a dominant presence in the brain-computer interface market.
See full Synchron company page
